title: Prognostic significance of beta-catenin nuclear expression in hepatocellular carcinoma.
abstract: OBJECTIVE
  There have been a few clinical reports about beta-catenin nuclear expression for hepatocellular carcinoma patients. However, the clinical significance of the nuclear expression has not been fully elucidated and remains to be controversial.
  
  
  METHODS
  We performed immunohistochemical examinations using an anti-beta-catenin monoclonal antibody for 101 hepatocellular carcinoma patients who underwent curative hepatic resection. Background factors and the disease-free survival were compared between hepatocellular carcinomas with and without beta-catenin nuclear expression. The prognostic factors influencing disease-free survival were examined by univariate and multivariate analyses.
  
  
  RESULTS
  Beta-catenin nuclear expression was judged as positive in 24 (23.8%) and negative in 77 (76.2%). Representative 3 hepatocellular carcinomas with beta-catenin nuclear expression showed the protein accumulation by Western blotting analysis. The clinicopathological analysis proved that vascular invasion was less prevalent in hepatocellular carcinomas with beta-catenin nuclear expression than in those without the expression (p=0.034). Hepatocellular carcinoma patients with beta-catenin nuclear expression had a longer disease-free survival than patients without the expression (p=0.035). Multivariate analysis proved that beta-catenin nuclear expression was selected as one of the independent factors related to disease-free survival (p=0.0054).
  
  
  CONCLUSIONS
  Our study demonstrated that beta-catenin nuclear expression is valuable as a prognostic factor for hepatocellular carcinoma patients who underwent hepatic resection.
authors.affiliation: Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Fujito
authors.forename: Yo
authors.initials: Y
authors.lastname: Sasaki
authors.forename: Kyoko
authors.initials: K
authors.lastname: Iwao
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Miyoshi
authors.forename: Terumasa
authors.initials: T
authors.lastname: Yamada
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ohigashi
authors.forename: Osamu
authors.initials: O
authors.lastname: Ishikawa
authors.forename: Shingi
authors.initials: S
authors.lastname: Imaoka
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D002467:Cell Nucleus / Q000378:metabolism*; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D013194:Staining and Labeling; D016019:Survival Analysis; D015534:Trans-Activators / Q000378:metabolism*; D051176:beta Catenin
chemical_list: D000911:Antibodies, Monoclonal; C495270:CTNNB1 protein, human; D003598:Cytoskeletal Proteins; D015534:Trans-Activators; D051176:beta Catenin